Synthesis and preclinical evaluation of radiolabeled alisertib as an investigational aurora kinase A PET tracer

被引：0
|
作者：
Verbeek, Joost [1 ]
Goos, Jeroen A. C. M. [1 ]
Geldof, Albert A. [1 ]
Hiemstra, Annemieke C. [1 ]
Hoekstra, Otto S. [1 ]
Meijer, Gerrit A. [1 ]
Stroud, Steven [2 ]
Bradley, Daniel [2 ]
Fijneman, Remond Ja [1 ]
Windhorst, Albert D. [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[2] Takeda Pharmaceut Int Co, Boston, MA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237)
    Goos, Jeroen A. C. M.
    Verbeek, Joost
    Geldof, Albert A.
    Hiernstra, Annemieke C.
    van de Wiel, Mark A.
    Adamzek, Kevin A.
    Delis-Van Diemen, Pien M.
    Stroud, Stephen G.
    Bradley, Daniel P.
    Meijer, Gerrit A.
    Hoekstra, Otto S.
    Fijneman, Remond J. A.
    Windhorst, Albert D.
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (01) : 63 - 72
  • [2] Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
    Palani, Santhosh
    Patel, Mayankbhai
    Huck, Jessica
    Zhang, Mengkun
    Balani, Suresh K.
    Yang, Johnny
    Chen, Susan
    Mettetal, Jerome
    Manfredi, Mark
    Shyu, Wen Chyi
    Ecsedy, Jeffrey A.
    Chakravarty, Arijit
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1255 - 1264
  • [3] Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
    Santhosh Palani
    Mayankbhai Patel
    Jessica Huck
    Mengkun Zhang
    Suresh K. Balani
    Johnny Yang
    Susan Chen
    Jerome Mettetal
    Mark Manfredi
    Wen Chyi Shyu
    Jeffrey A. Ecsedy
    Arijit Chakravarty
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1255 - 1264
  • [4] Synthesis and preclinical evaluation of [11C]/[3H]Alisertib, an aurora kinase A (AURKA) inhibitor
    Verbeek, Joost
    Goos, Jeroen A.
    Hiemstra, Annemieke
    Delis-van Diemen, Pien
    Geldof, Albert
    Hoekstra, Otto
    Stroud, Steven
    Bradley, Daniel
    Meijer, Gerrit
    Fijneman, Remond
    Windhorst, Albert D.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2015, 58 : S335 - S335
  • [5] Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
    Xiaofei Zhou
    John Nemunaitis
    Shubham Pant
    Todd M. Bauer
    Manish Patel
    John Sarantopoulos
    A. Craig Lockhart
    Daniel Goodman
    Dirk Huebner
    Diane R. Mould
    Karthik Venkatakrishnan
    Investigational New Drugs, 2018, 36 : 240 - 247
  • [6] Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
    Zhou, Xiaofei
    Nemunaitis, John
    Pant, Shubham
    Bauer, Todd M.
    Patel, Manish
    Sarantopoulos, John
    Lockhart, A. Craig
    Goodman, Daniel
    Huebner, Dirk
    Mould, Diane R.
    Venkatakrishnan, Karthik
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 240 - 247
  • [7] The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin
    Zullo, Kelly
    Guo, Yige
    Cooke, Laurence
    Serrano, Xavier Jirau
    Mangone, Michael
    Scotto, Luigi
    Amengual, Jennifer E.
    Mahadevan, Daruka
    O'Connor, Owen A.
    BLOOD, 2014, 124 (21)
  • [8] Scientific rationale supporting the clinical development strategy for the investigational Aurora A kinase inhibitor alisertib in cancer
    Niu, Huifeng
    Manfredi, Mark
    Ecsedy, Jeffrey A.
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [9] Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
    Xiaofei Zhou
    Shubham Pant
    John Nemunaitis
    A. Craig Lockhart
    Gerald Falchook
    Todd M. Bauer
    Manish Patel
    John Sarantopoulos
    Michael Bargfrede
    Andreas Muehler
    Lakshmi Rangachari
    Bin Zhang
    Karthik Venkatakrishnan
    Investigational New Drugs, 2018, 36 : 248 - 258
  • [10] The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas
    Sehdev, Vikas
    Katsha, Ahmed
    Ecsedy, Jeffrey
    Zaika, Alexander
    Belkhiri, Abbes
    El-Rifai, Wael
    CANCER, 2013, 119 (04) : 904 - 914
12345